© 2024 Western New York Public Broadcasting Association

140 Lower Terrace
Buffalo, NY 14202

Mailing Address:
Horizons Plaza P.O. Box 1263
Buffalo, NY 14240-1263

Buffalo Toronto Public Media | Phone 716-845-7000
WBFO Newsroom | Phone: 716-845-7040
Your NPR Station
Play Live Radio
Next Up:
0:00 0:00
Available On Air Stations

Testing melanoma vaccine at Roswell

Photo from Roswell Park Website

Vaccination is a word usually associated with preventing a disease, measles or polio vaccination. But as WBFO'S  Mike Desmond reports, researchers at Roswell Park Cancer Institute are testing a vaccine to fight melanoma.

"The research that we've been doing is sort of building on the idea that for melanoma  immune stimulation is really the way to go," said Dr. John Kane, lead researcher on the grant and chief of the Melanoma/Sarcoma Service in the Surgical Oncology Department at Roswell. 

Dr. Kane said the basic process is a vaccination to pump up the immune system of a patient with the deadly skin cancer.

"There are very few traditional chemotherapies that have been affective in melanoma," said Dr. Kane.

Researchers and surgeons are using a federal grant to treat late stage melanoma skin cancer.

As many as 20 patients will receive the new vaccine to test its safety, mixing what's called a heat-shock protein studied at the cancer center with an antigen, which is supposed to help the immune system beat back the skin tumor.

Listen to Dr. John Kane, lead researcher on the grant and chief of the Melanoma/Sarcoma Service in the Surgical Oncology Department at Roswell explains the use of vaccine.

"One of the ways that we routinely stimulate the  immune system is through vaccination," said Dr. Kane.

Dr.  Kane said it's important because melanoma is a problem for all races.

"It is clearly more common in the Caucasian population. But, for example, African-Americans can get melanoma. It tends to be different variants. So,if you look at what we call acral lentiginous melanoma, palms of the hand, souls of the feet, growing under the fingernails or toe nails, it's the rarest sub-type, but it's the most common sub-type in African-Americans and people of Asian descent," said Dr. Kane.

Dr. Kane said if this three-year trial goes well, there will be more patients treated at other hospitals and the technology might be applied to other cancers.

"All of the new treatments that have been in the news, and the New England Journal, many of them have been immune based," said Dr. Kane.

There's more public awareness of melanoma. It's more visible because it's on the skin surface, so it's often spotted early by victims as well as by doctors.

The National Cancer Institute estimates 77,000 new cases this year and 9,000 deaths.

Mike Desmond is one of Western New York’s most experienced reporters, having spent nearly a half-century covering the region for newspapers, television stations and public radio. He has been with WBFO and its predecessor, WNED-AM, since 1988. As a reporter for WBFO, he has covered literally thousands of stories involving education, science, business, the environment and many other issues. Mike has been a long-time theater reviewer for a variety of publications and was formerly a part-time reporter for The New York Times.